120 related articles for article (PubMed ID: 36996696)
21. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
[TBL] [Abstract][Full Text] [Related]
22. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
[TBL] [Abstract][Full Text] [Related]
23. Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis.
Park HR; Kim SE; Keam B; Chung H; Seok SH; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
Sci Rep; 2022 Jul; 12(1):12546. PubMed ID: 35869130
[TBL] [Abstract][Full Text] [Related]
24. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
[TBL] [Abstract][Full Text] [Related]
25. Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.
Cheng L; Zhang X; Tang J; Lv Q; Liu J
Biomaterials; 2021 Aug; 275():120964. PubMed ID: 34147721
[TBL] [Abstract][Full Text] [Related]
26. Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia.
Melo Garcia L; Barabé F
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944878
[TBL] [Abstract][Full Text] [Related]
27. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
[TBL] [Abstract][Full Text] [Related]
28. A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a "Glutamine Trap" To Inhibit Lung Cancer Cell Growth.
Wu J; Li Z; Yang Z; Guo L; Zhang Y; Deng H; Wang C; Feng M
Mol Pharm; 2018 Aug; 15(8):3032-3045. PubMed ID: 29939755
[TBL] [Abstract][Full Text] [Related]
29. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
[TBL] [Abstract][Full Text] [Related]
30. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
[TBL] [Abstract][Full Text] [Related]
31. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
[TBL] [Abstract][Full Text] [Related]
32. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
[No Abstract] [Full Text] [Related]
33. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
34. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.
Chao MP; Jaiswal S; Weissman-Tsukamoto R; Alizadeh AA; Gentles AJ; Volkmer J; Weiskopf K; Willingham SB; Raveh T; Park CY; Majeti R; Weissman IL
Sci Transl Med; 2010 Dec; 2(63):63ra94. PubMed ID: 21178137
[TBL] [Abstract][Full Text] [Related]
35. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
36. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
[TBL] [Abstract][Full Text] [Related]
37. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis.
Li J; Yan S; Li Q; Huang Y; Ji M; Jiao X; Yuan M; Wang G
Mol Hum Reprod; 2022 Apr; 28(5):. PubMed ID: 35404426
[TBL] [Abstract][Full Text] [Related]
38. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
39. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
[TBL] [Abstract][Full Text] [Related]
40. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.
Michaels AD; Newhook TE; Adair SJ; Morioka S; Goudreau BJ; Nagdas S; Mullen MG; Persily JB; Bullock TNJ; Slingluff CL; Ravichandran KS; Parsons JT; Bauer TW
Clin Cancer Res; 2018 Mar; 24(6):1415-1425. PubMed ID: 29288236
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]